Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study

The Lancet Diabetes & Endocrinology 2026

View at publisher
Authors: John B Buse, Harpreet S Bajaj, Stine‐Mathilde Dalskov, Lucienne Donaldson, Helene H Hansen Duus, Therese W. Fabricius, Martin Haluzík, Ildiko Lingvay, Sue D Pedersen, Richard E Pratley, Akshay B Jain
DOI: 10.1016/s2213-8587(26)00125-7
Cited by: 9
References: 26

Fields of Study & Subjects

Diabetes Treatment and Management Diabetes Cardiovascular Risks and Lipoproteins Lipoproteins and Cardiovascular Health

Publication details

Journal / source
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Volume
14
Issue
8
Pages
662–677
Publication date
7 June 2026
Language
EN